DanCann Pharma A/S (NGM:DANCAN)

Market Cap	8.31M
Revenue (ttm)	11.33M
Net Income (ttm)	-12.82M
Shares Out	3.99M
EPS (ttm)	-3.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,773
Average Volume	24,012
Open	1.450
Previous Close	1.250
Day's Range	1.250 - 1.450
52-Week Range	n/a
Beta	2.13
RSI	44.60
Earnings Date	Apr 4, 2025

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 12
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2024, DanCann Pharma's revenue was 7.37 million, an increase of 3.06% compared to the previous year's 7.15 million. Losses were -8.35 million, -86.59% less than in 2023.

Financial numbers in DKK